Catalyst Wire Dossier Catalyst Wire Dossier

PI3K-mTOR pathway inhibitor (unspecified)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PI3K-mTOR pathway inhibitor (unspecified), covering 2016-08-25 to 2016-08-25. Get the full timeline:

Most recent: Clinical Trial Update: Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients [Phase 1, Phase 2]

See pricing